Published on August 25, 2014

Since last two years after the drug price control order by the government, curbed prices of drug that had impact the margins of the pharmaceutical industries, led to posting dreary quarterly performance and after the month of April, 2014 the drug makers were allowed increase their prices which in turn have helped the companies to hold up their domestic business in the second quarter of 2014.

In the first quarter of 2014 most of the major drugs manufacturers have reported a double-digit growth, moreover after a dreary performance last year, in the second quarter of 2014 in the domestic business on the back of price hikes an impressive growth has been recorded by most Indian pharma industries, as per the researched report.

Furthermore at the end of the second quarter of 2014 against an average industry growth of 8%, major pharma manufacturers in the local market such as Glenmark, Dr Reddy's Labs, Sun Pharma, Lupin and Cipla have even registered a strong double-digit growth. According to the researched report, in the second quarter of 2014 major pharma producers such as Lupin and Glenmark in the domestic business had witnessed 29% and 20.87% growth at Rs. 761.5 crore and Rs. 397.15 crore, respectively whereas Cipla and Sun Pharma had account 17% growth at Rs. 1,289 crore and Rs. 992 crore, respectively. Moreover India business of Dr Reddy's Labs had augment to 15% to Rs 400 crore.

As per the researched report in the midst of several alternatives India is currently noted as the most competitive pharmaceutical market in the world and at different price points a wealthy generics industry for each drug were available, also the durable health and structure of this sector is being coerce through an unforeseen move of the regulators and arbitrary.